Summary:
- Viking Therapeutics reported positive topline data from a Phase 2 maintenance study of VK2735, a dual GLP-1/GIP receptor agonist designed for the treatment of obesity.
- The study demonstrated that multiple maintenance dosing regimens were effective in sustaining weight loss initially achieved during the induction phase, highlighting the drug's potential for long-term weight management.
- The findings provide critical clinical evidence regarding the pharmacodynamics and safety profile of dual-agonist therapies in metabolic disease regulation.